Other

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

E. R. Squibb Sons, Inc.

Université Louis Pasteur

Manuel Mark

Pierre H Chambon

Philippe Kastner

Marianne Lemeur

Andree Dierich

Thomas Lufkin

David Lohnes

Cathy Mendelsohn

Philippe Gorry

Daniel Metzger

Norbert B Ghyselinck

Val&eacute;rie Dup&eacute;

Emiliana Borrelli

The invention relates to methods for treatment of neurological disease by administering an agent which interacts with a retinoid receptor associated with the neurological disease. The invention is also related to a method of modulating dopamine receptor synthesis by introducing an agent that interacts with a retinoid receptor associated with the dopamine receptor synthesis. The invention is further related to a transgenic animal, e.g., mouse, and mammalian cell line, which is deficient in the normal synthesis of one or more receptors of RAR&agr;, &bgr;, &ggr; and RXR, and cell line thereof.

Use of ligands for treatment of diseases responsive to retinoids

The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, to mice heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptors, or the normal expression thereof, is desirable.

Genetically engineered mice containing alterations in the genes encoding retinoic acid receptor proteins

Genetically engineered mice and cell lines containing alterations in the

Genetically engineered mice containing alterations in the genes encoding

Growing community of inventors

Morchwiller, France

Manuel Mark